Elevated pretreatment serum CA-125 levels have been substantially associated with adverse prognostic indicators in EC patients, affirming the marker’s effectiveness in prognostication, similar to findings in OC (67) and other malignancies such as bladder urothelial carcinoma (68), pancreatic ductal adenocarcinoma (69), and renal cell carcinoma (70). This evidence concerns the gene MUC16 and hereditary clear cell renal cell carcinoma.